Targeting Chemoresistant Tumors: Could TRIM Proteins-p53 Axis Be a Possible Answer?

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tumor heterogeneity and adaptability drive chemoresistance, significantly impacting cancer treatment efficacy.
• Tripartite motif (TRIM) proteins, through E3-ubiquitin ligase and other activities, are implicated in diverse chemoresistance mechanisms.
• The interaction of TRIM proteins with the p53 tumor suppressor is a critical link to chemoresistance.

Purpose of the Study:

• To explore the multifaceted roles of TRIM proteins in the development of chemoresistance.
• To elucidate the mechanisms by which TRIM proteins modulate p53 stability and activity.
• To investigate TRIM protein involvement in p53-independent chemoresistance pathways.

Main Methods:

• Review of existing literature on TRIM proteins, p53 regulation, and chemoresistance pathways.
• Analysis of TRIM protein functions including E3-ubiquitin ligase activity and interactions with cellular signaling pathways.
• Examination of TRIM protein's impact on p53 degradation, localization, and target gene transactivation.

Main Results:

• TRIM proteins modulate p53 protein stability, localization, and transactivation, influencing cellular responses to therapy.
• TRIM proteins contribute to chemoresistance through p53-dependent and p53-independent mechanisms.
• Key signaling pathways like PI3K/Akt/NF-κB and Wnt/beta-catenin are affected by TRIM proteins in chemoresistance.

Conclusions:

• TRIM proteins are significant regulators of chemoresistance in various cancers.
• Targeting TRIM protein function presents a potential therapeutic strategy to overcome chemoresistance.
• Further investigation into TRIM protein modulation could enhance the effectiveness of anticancer treatments.